Two leading biotechnology companies are competing to be the first to implement cheaper, faster processes for producing drugs inside living cells, making it easier to manufacture human proteins, antibodies, and other medications.
The new approaches will be “disruptively different” says Robert Bradway, the CEO of Amgen, one of the companies pursuing a manufacturing breakthrough. Today’s systems for producing drugs in bacterial or animal cells and then isolating them are hugely expensive and can take months. With more efficient processes in place, companies could swiftly increase production of drugs in high demand, and they could produce medicines for rare diseases more cost-effectively as well.